DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
1404
PARSATUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Non-Small-Cell Lung
Epidermal growth factor-like protein 7 inhibitor
PARSATUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
435M4HCP2M
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VIPALANEBART
2
Antibody
Unknown
Unknown
Unknown
Migraine Disorders
Unknown
VIPALANEBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ENVAFOLIMAB
2
Antibody
Investigational
Unknown
Unknown
Adenocarcinoma; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Gallbladder Neoplasms; Hepatitis B, Chronic; HIV Infections; Lung Neoplasms; Meningeal Carcinomatosis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Sarcoma; Stomach Neoplasms; Uterine Cervical Neoplasms; Rectal Neoplasms
Programmed cell death 1 ligand 1 binding agent
ENVAFOLIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
ES1M06M6QH
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
A33 131I
2
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms
Cell surface A33 antigen binding agent
A33 131I
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RALUDOTATUG
2
Antibody
Unknown
Unknown
Unknown
Neoplasms
Unknown
RALUDOTATUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ANTI-CD18
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
ANTI-CD18
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TELIMOMAB ARITOX
2
Antibody
Investigational
Unknown
Unknown
Hepatitis B, Chronic
80S Ribosome inhibitor
TELIMOMAB ARITOX
×
Maximum Phase:
2
First Approval:
None
UNII:
A69GKQ6QV6
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CASDOZOKITUG
2
Antibody
Unknown
Unknown
Unknown
Neoplasms; Carcinoma, Hepatocellular
Unknown
CASDOZOKITUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EPACMARSTOBART
2
Antibody
Unknown
Unknown
Unknown
Lymphoma, Non-Hodgkin; Neoplasms
Unknown
EPACMARSTOBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NI-0801
2
Antibody
Investigational
Unknown
Unknown
Dermatitis, Allergic Contact; Liver Cirrhosis, Biliary
C-X-C motif chemokine 10 inhibitor
NI-0801
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ZOLIMOMAB ARITOX
2
Antibody
Investigational
Unknown
Unknown
Unknown
80S Ribosome inhibitor
ZOLIMOMAB ARITOX
×
Maximum Phase:
2
First Approval:
None
UNII:
2C1ZT922TD
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ZALIFRELIMAB
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Pancreatic Ductal; Diffuse Intrinsic Pontine Glioma; Neoplasms; Carcinoma, Non-Small-Cell Lung; Hemangiosarcoma; Sarcoma; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms
Cytotoxic T-lymphocyte protein 4 inhibitor
ZALIFRELIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
FE7L22H028
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OLINVACIMAB
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Glioblastoma; Triple Negative Breast Neoplasms
Vascular endothelial growth factor receptor 2 inhibitor
OLINVACIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
VFH55IZ5VI
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
F16IL2
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Leukemia, Myeloid, Acute; Carcinoma, Merkel Cell
Tenascin other
F16IL2
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TOBEVIBART
2
Antibody
Unknown
Unknown
Unknown
Hepatitis B; Hepatitis B, Chronic; Hepatitis D
Unknown
TOBEVIBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IMEROPRUBART
2
Antibody
Unknown
Unknown
Unknown
Autoimmune Diseases
Unknown
IMEROPRUBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MEZAGITAMAB
2
Antibody
Investigational
Unknown
Unknown
Autoimmune Diseases; Glomerulonephritis; Lupus Erythematosus, Systemic; Multiple Myeloma; Neoplasms; Myasthenia Gravis; Purpura, Thrombocytopenic, Idiopathic
Lymphocyte differentiation antigen CD38 binding agent
MEZAGITAMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
0XMR8L9LOL
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TNX-650
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
TNX-650
×
Maximum Phase:
2
First Approval:
None
UNII:
U9JLP7V031
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SAMALIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Multiple Myeloma; Neoplasms
OX-2 membrane glycoprotein inhibitor
SAMALIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
64EUX713G6
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RG-7652
2
Antibody
Investigational
Unknown
Unknown
Unknown
Subtilisin/kexin type 9 inhibitor
RG-7652
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SILEVIMIG
2
Antibody
Unknown
Unknown
Unknown
Virus Diseases
Unknown
SILEVIMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
3F8
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
3F8
×
Maximum Phase:
2
First Approval:
None
UNII:
3GFS72WN4M
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PEGRIZEPRUMENT
2
Antibody
Unknown
Unknown
Unknown
Autoimmune Diseases
Unknown
PEGRIZEPRUMENT
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMLENETUG
2
Antibody
Unknown
Unknown
Unknown
Parkinson Disease; Multiple System Atrophy
Unknown
AMLENETUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EMFIZATAMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
EMFIZATAMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
FB8PCJ9N3H
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RILOGROTUG
2
Antibody
Unknown
Unknown
Unknown
Cachexia
Unknown
RILOGROTUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ARMOCIBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
ARMOCIBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VONSETAMIG
2
Antibody
Unknown
Unknown
Unknown
Neoplasms
Unknown
VONSETAMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
APITEGROMAB
2
Antibody
Investigational
Unknown
Unknown
Obesity; Atrophy; Muscular Atrophy, Spinal; Spinal Muscular Atrophies of Childhood
Growth/differentiation factor 8 inhibitor
APITEGROMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
UZ54216N0Y
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
UPREVSTOBART
2
Antibody
Unknown
Unknown
Unknown
Neoplasms
Unknown
UPREVSTOBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ISTIRATUMAB
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Pancreatic Neoplasms
Insulin-like growth factor I receptor inhibitor
ISTIRATUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
XLR461MD3M
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VENANPRUBART
2
Antibody
Unknown
Unknown
Unknown
Autoimmune Diseases; Psoriasis; Lupus Erythematosus, Systemic; Sjogren's Syndrome
Unknown
VENANPRUBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CIDUVECTAMIG
2
Antibody
Unknown
Unknown
Unknown
Neoplasms
Unknown
CIDUVECTAMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EXBIVIRUMAB
2
Antibody
Investigational
Unknown
Unknown
Hepatitis B, Chronic
Major surface antigen binding agent
EXBIVIRUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
5Q374M1S1P
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LIFASTUZUMAB VEDOTIN
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms
Sodium-dependent phosphate transport protein 2B binding agent
LIFASTUZUMAB VEDOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
7IUT83FK6S
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
19
20
21
22
23
24
25
…
40
41
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA